
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7054163/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Overcoming barriers in the design and implementation of clinical trials for acute kidney injury: a report from the 2020 Kidney Disease Clinical Trialists meeting. Nephrology Dialysis Transplantation, 2023, 38, 834-844.	0.7	14
2	Opioids for chronic pain management in patients with dialysis-dependent kidney failure. Nature Reviews Nephrology, 2022, 18, 113-128.	9.6	14
3	A Qualitative Study of Facilitators and Barriers to Self-Management of CKD. Kidney International Reports, 2022, 7, 46-55.	0.8	10
4	What Patients Teach Us About Patient Engagement in Research. Clinical Journal of the American Society of Nephrology: CJASN, 2022, 17, 176-178.	4.5	1
5	The Microbiome and p-Inulin in Hemodialysis: A Feasibility Study. Kidney360, 2021, 2, 445-455.	2.1	3
6	Nonpharmacologic Treatments for Opioid Reduction in Patients With Advanced Chronic Kidney Disease. Seminars in Nephrology, 2021, 41, 68-81.	1.6	4
7	Effect of Kidney Function on Relationships between Lifestyle Behaviors and Mortality or Cardiovascular Outcomes: A Pooled Cohort Analysis. Journal of the American Society of Nephrology: JASN, 2021, 32, 663-675.	6.1	19
8	Integrating Conservative kidney management Options and advance care Planning Education (COPE) into routine CKD care: a protocol for a pilot randomised controlled trial. BMJ Open, 2021, 11, e042620.	1.9	3
9	MO214EVALUATION OF THE EFFECT OF A POTASSIUM BINDER ON ARRHYTHMIA-RELATED CARDIOVASCULAR OUTCOMES IN PATIENTS ON CHRONIC HAEMODIALYSIS WITH RECURRENT HYPERKALAEMIA: DESIGN AND RATIONALE FOR THE SODIUM ZIRCONIUM CYCLOSILICATE DIALIZE-OUTCOMES STUDY. Nephrology Dialysis Transplantation. 2021. 36.	0.7	0
10	Design and Rationale of HiLo: A Pragmatic, Randomized Trial of Phosphate Management for Patients Receiving Maintenance Hemodialysis. American Journal of Kidney Diseases, 2021, 77, 920-930.e1.	1.9	23
11	Mobile Health (mHealth) Technology: Assessment of Availability, Acceptability, and Use in CKD. American Journal of Kidney Diseases, 2021, 77, 941-950.e1.	1.9	49
12	Accounting for quality improvement during the conduct of embedded pragmatic clinical trials within healthcare systems: NIH Collaboratory case studies. Healthcare, 2021, 8, 100432.	1.3	1
13	Celebrating 4 Decades of AJKD. American Journal of Kidney Diseases, 2021, 78, 1-2.	1.9	1
14	Arteriovenous Fistula Maturation, Functional Patency, and Intervention Rates. JAMA Surgery, 2021, 156, 1111.	4.3	45
15	Novel Risk Factors for Progression of Diabetic and Nondiabetic CKD: Findings From the Chronic Renal Insufficiency Cohort (CRIC) Study. American Journal of Kidney Diseases, 2021, 77, 56-73.e1.	1.9	45
16	Suitability for Kidney Transplantation in AL Amyloidosis: A Survey Study of Transplant and Amyloidosis Physicians. Kidney360, 2021, 2, 10.34067/KID.0004232021.	2.1	2
17	Indoleamine 2,3-dioxygenase-1, a Novel Therapeutic Target for Post-Vascular Injury Thrombosis in CKD. Journal of the American Society of Nephrology: JASN, 2021, 32, 2834-2850.	6.1	6
18	Pain management in patients with chronic kidney disease and end-stage kidney disease. Current Opinion in Nephrology and Hypertension, 2020, 29, 671-680.	2.0	25

#	Article	IF	CITATIONS
19	Combination Hydralazine and Isosorbide Dinitrate in Dialysis-Dependent ESRD (HIDE): A Randomized, Placebo-Controlled, Pilot Trial. Kidney360, 2020, 1, 1380-1389.	2.1	2
20	Improving Care for Patients after Hospitalization with AKI. Journal of the American Society of Nephrology: JASN, 2020, 31, 2237-2241.	6.1	24
21	Drug Development in Kidney Disease: Proceedings From a Multistakeholder Conference. American Journal of Kidney Diseases, 2020, 76, 842-850.	1.9	4
22	Sex and the kidneys: current understanding and research opportunities. Nature Reviews Nephrology, 2019, 15, 776-783.	9.6	68
23	Ethical Issues in Pragmatic Cluster-Randomized Trials in Dialysis Facilities. American Journal of Kidney Diseases, 2019, 74, 659-666.	1.9	6
24	Addressing guideline and policy changes during pragmatic clinical trials. Clinical Trials, 2019, 16, 431-437.	1.6	7
25	Mineral Metabolism Disturbances and Arteriovenous Fistula Maturation. European Journal of Vascular and Endovascular Surgery, 2019, 57, 719-728.	1.5	10
26	The TiME Trial: A Fully Embedded, Cluster-Randomized, Pragmatic Trial of Hemodialysis Session Duration. Journal of the American Society of Nephrology: JASN, 2019, 30, 890-903.	6.1	38
27	Dialysis initiation, modality choice, access, and prescription: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney International, 2019, 96, 37-47.	5.2	235
28	The authors reply. Kidney International, 2019, 95, 468.	5.2	0
29	The home hemodialysis patient experience: A qualitative assessment of modality use and discontinuation. Hemodialysis International, 2019, 23, 139-150.	0.9	10
30	A Pragmatic Step Forward: AKI and Beyond. Journal of the American Society of Nephrology: JASN, 2019, 30, 371-372.	6.1	3
31	Cultivating Innovative Pragmatic Cluster-Randomized Registry Trials Embedded in Hemodialysis Care: Workshop Proceedings From 2018. Canadian Journal of Kidney Health and Disease, 2019, 6, 205435811989439.	1.1	7
32	Safety and cardiovascular efficacy of spironolactone in dialysis-dependent ESRD (SPin-D): a randomized, placebo-controlled, multiple dosage trial. Kidney International, 2019, 95, 973-982.	5.2	70
33	Perspectives on Research Participation and Facilitation Among Dialysis Patients, Clinic Personnel, and Medical Providers: A Focus Group Study. American Journal of Kidney Diseases, 2018, 72, 93-103.	1.9	14
34	Relationships Between Clinical Processes and Arteriovenous Fistula Cannulation and Maturation: AÂMulticenter Prospective Cohort Study. American Journal of Kidney Diseases, 2018, 71, 677-689.	1.9	59
35	Uremic Solute-Aryl Hydrocarbon Receptor-Tissue Factor Axis Associates with Thrombosis after Vascular Injury in Humans. Journal of the American Society of Nephrology: JASN, 2018, 29, 1063-1072.	6.1	76
36	Overcoming Translational Barriers in Acute Kidney Injury. Clinical Journal of the American Society of Nephrology: CJASN, 2018, 13, 1113-1123.	4.5	36

#	Article	IF	CITATIONS
37	Patient and Kidney Allograft Survival in Recipients With End-Stage Renal Disease From Amyloidosis. Transplantation, 2018, 102, 300-309.	1.0	15
38	Prediction of Arteriovenous Fistula Clinical Maturation from Postoperative Ultrasound Measurements: Findings from the Hemodialysis Fistula Maturation Study. Journal of the American Society of Nephrology: JASN, 2018, 29, 2735-2744.	6.1	103
39	Local Adipose-Associated Mediators andÂAdaptations Following Arteriovenous Fistula Creation. Kidney International Reports, 2018, 3, 970-978.	0.8	5
40	A clone-directed approach may improve diagnosis and treatment of proliferative glomerulonephritis with monoclonal immunoglobulin deposits. Kidney International, 2018, 94, 199-205.	5.2	90
41	High-Dose Melphalan and Stem Cell Transplantation in Patients on Dialysis Due to Immunoglobulin Light-Chain Amyloidosis and Monoclonal Immunoglobulin Deposition Disease. Biology of Blood and Marrow Transplantation, 2018, 24, 127-132.	2.0	31
42	The Use of a Multidimensional Measure of Dialysis Adequacy—Moving beyond Small Solute Kinetics. Clinical Journal of the American Society of Nephrology: CJASN, 2017, 12, 839-847.	4.5	62
43	Intimal Hyperplasia, Stenosis, and Arteriovenous Fistula Maturation Failure in the Hemodialysis Fistula Maturation Study. Journal of the American Society of Nephrology: JASN, 2017, 28, 3005-3013.	6.1	96
44	Endothelium-Dependent and -Independent Vascular Function in Advanced Chronic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2017, 12, 1588-1594.	4.5	45
45	Smooth Muscle Nitric Oxide Responsiveness and Clinical Maturation of Hemodialysis Arteriovenous Fistulae. American Journal of Pathology, 2017, 187, 2095-2101.	3.8	7
46	Data Sharing and Embedded Research. Annals of Internal Medicine, 2017, 167, 668.	3.9	18
47	Pragmatic clinical trials embedded in healthcare systems: generalizable lessons from the NIH Collaboratory. BMC Medical Research Methodology, 2017, 17, 144.	3.1	127
48	Willingness to participate in pragmatic dialysis trials: the importance of physician decisional autonomy and consent approach. Trials, 2017, 18, 474.	1.6	5
49	Patient and physician views about protocolized dialysis treatment in randomized trials and clinical care. AJOB Empirical Bioethics, 2016, 7, 106-115.	1.6	16
50	Pragmatic Trials in Maintenance Dialysis: Perspectives from the Kidney Health Initiative. Journal of the American Society of Nephrology: JASN, 2016, 27, 2955-2963.	6.1	33
51	Vascular Function at Baseline in the Hemodialysis Fistula Maturation Study. Journal of the American Heart Association, 2016, 5, .	3.7	10
52	Use of PRECIS ratings in the National Institutes of Health (NIH) Health Care Systems Research Collaboratory. Trials, 2016, 17, 32.	1.6	49
53	Trials without tribulations: Minimizing the burden of pragmatic research on healthcare systems. Healthcare, 2016, 4, 138-141.	1.3	11
54	The effect of location and configuration on forearm and upper arm hemodialysis arteriovenous grafts. Journal of Vascular Surgery, 2015, 62, 1258-1265.	1.1	25

#	Article	IF	CITATIONS
55	A guide to research partnerships for pragmatic clinical trials. BMJ, The, 2014, 349, g6826-g6826.	6.0	54
56	Notch Ties a Knot on Fistula Maturation. Journal of the American Society of Nephrology: JASN, 2014, 25, 648-650.	6.1	3
57	Objectives and Design of the Hemodialysis Fistula Maturation Study. American Journal of Kidney Diseases, 2014, 63, 104-112.	1.9	115
58	Human type I pancreatic elastase treatment of arteriovenous fistulas in patients with chronic kidney disease. Journal of Vascular Surgery, 2014, 60, 454-461.e1.	1.1	45
59	Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients. Blood, 2011, 118, 4346-4352.	1.4	259
60	High-Dose Melphalan and Autologous Stem Cell Transplantation In AL Amyloidosis and Monoclonal Immunoglobulin Deposition Disease Associated End-Stage Renal Disease Requiring Dialysis. Blood, 2010, 116, 3553-3553.	1.4	1
61	Modern Treatment of Amyloidosis: Unresolved Questions: Table 1 Journal of the American Society of Nephrology: JASN, 2009, 20, 469-472.	6.1	27
62	Effect of Dipyridamole plus Aspirin on Hemodialysis Graft Patency. New England Journal of Medicine, 2009, 360, 2191-2201.	27.0	265
63	Effect of Clopidogrel on Early Failure of Arteriovenous Fistulas for Hemodialysis. JAMA - Journal of the American Medical Association, 2008, 299, 2164.	7.4	700
64	Eprodisate for the Treatment of Renal Disease in AA Amyloidosis. New England Journal of Medicine, 2007, 356, 2349-2360.	27.0	240
65	UNRESOLVED ISSUES IN DIALYSIS: Dialysisâ€Related Amyloidosis: Late Finding or Hidden Epidemic?. Seminars in Dialysis, 2006, 19, 105-109.	1.3	76
66	Light Chains, Casts, Sheets and Fibrils: Monoclonal Immunoglobulin Diseases and Immunotactoid/Fibrillary Glomerulopathy. Clinical Journal of the American Society of Nephrology: CJASN, 2006, 1, 1320-1321.	4.5	7
67	Amyloidosis-Associated Kidney Disease. Journal of the American Society of Nephrology: JASN, 2006, 17, 3458-3471.	6.1	332
68	Design of the Dialysis Access Consortium (DAC) clopidogrel prevention of early AV fistula thrombosis trial. Clinical Trials, 2005, 2, 413-422.	1.6	47
69	Case 15-2005. New England Journal of Medicine, 2005, 352, 2111-2119.	27.0	15
70	Thrombosis in End‣tage Renal Disease. Seminars in Dialysis, 2003, 16, 245-256.	1.3	133
71	Critical care issues in the patient with chronic renal failure. Critical Care Clinics, 2002, 18, 421-440.	2.6	12